首页> 外文期刊>Frontiers in Pharmacology >Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1
【24h】

Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1

机译:通心络抑制miR-128-3p通过上调p70s6k1 / p-p70s6k1保护人心肌细胞免受缺血/再灌注损伤

获取原文
       

摘要

Background and Aims: Tongxinluo (TXL) is a multifunctional traditional Chinese medicine that has been widely used to treat cardiovascular and cerebrovascular diseases. However, no studies have explored whether TXL can protect human cardiomyocytes (HCMs) from ischemia/reperfusion (I/R) injury. Reperfusion Injury Salvage Kinase (RISK) pathway activation was previously demonstrated to protect the hearts against I/R injury and it is generally activated via Akt or (and) Erk 1/2, and their common downstream protein, ribosomal protein S6 kinase (p70s6k). In addition, prior studies proved that TXL treatment of cells promoted secretion of VEGF, which could be stimulated by the increased phosphorylation of one p70s6k subtype, p70s6k1. Consequently, we hypothesized TXL could protect HCMs from I/R injury by activating p70s6k1 and investigated the underlying mechanism. Methods and Results: HCMs were exposed to hypoxia (18 h) and reoxygenation (2 h) (H/R), with or without TXL pretreatment. H/R reduced mitochondrial membrane potential, increased bax/bcl-2 ratios and cytochrome C levels and induced HCM apoptosis. TXL preconditioning reversed these H/R-induced changes in a dose-dependent manner and was most effective at 400 μg/mL. The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k. However, inhibitors of Erk1/2 (U0126) or Akt (LY294002) failed to inhibit the protective effect of TXL. TXL increased p70s6k1 expression and, thus, enhanced its phosphorylation. Furthermore, transfection of cardiomyocytes with siRNA to p70s6k1 abolished the protective effects of TXL. Among the micro-RNAs (miR-145-5p, miR-128-3p and miR-497-5p) previously reported to target p70s6k1, TXL downregulated miR-128-3p in HCMs during H/R, but had no effects on miR-145-5p and miR-497-5p. An in vivo study confirmed the role of the p70s6k1 pathway in the infarct-sparing effect of TXL, demonstrating that TXL decreased miR-128-3p levels in the rat myocardium during I/R. Transfection of HCMs with a hsa-miR-128-3p mimic eliminated the protective effects of TXL. Conclusions: The miR-128-3p/p70s6k1 signaling pathway is involved in protection by TXL against HCM apoptosis during H/R. Overexpression of p70s6k1 is, therefore, a potential new strategy for alleviating myocardial reperfusion injury.
机译:背景与目的:通心络(TXL)是一种多功能中药,已被广泛用于治疗心脑血管疾病。但是,尚无研究探讨TXL是否能保护人类心肌细胞(HCM)免受缺血/再灌注(I / R)损伤。先前已证明再灌注损伤抢救激酶(RISK)途径可保护心脏免受I / R损伤,并且通常通过Akt或(和)Erk 1/2及其常见的下游蛋白核糖体蛋白S6激酶(p70s6k)激活。 。此外,先前的研究证明,对细胞进行TXL处理可促进VEGF的分泌,而这可能是由一种p70s6k亚型p70s6k1的磷酸化增加所刺激的。因此,我们假设TXL可以通过激活p70s6k1来保护HCM免受I / R损伤,并研究了其潜在机制。方法和结果:HCMs接受或不接受TXL预处理均暴露于缺氧(18 h)和复氧(2 h)(H / R)。 H / R降低线粒体膜电位,增加bax / bcl-2比率和细胞色素C水平并诱导HCM凋亡。 TXL预处理以剂量依赖的方式逆转了这些H / R诱导的变化,并且在400μg/ mL时最有效。雷帕霉素(p70s6k的抑制剂)消除了TXL的抗凋亡作用。但是,Erk1 / 2(U0126)或Akt(LY294002)的抑制剂未能抑制TXL的保护作用。 TXL增加p70s6k1表达,并因此增强其磷酸化作用。此外,用siRNA转染心肌细胞至p70s6k1消除了TXL的保护作用。在先前报道靶向microRNA的microRNA(miR-145-5p,miR-128-3p和miR-497-5p)中,tXL在H / R期间下调了HCM中的miR-128-3p,但对miR没有影响-145-5p和miR-497-5p。一项体内研究证实了p70s6k1通路在TXL梗死抑制作用中的作用,表明TXL在I / R期间降低了大鼠心肌中的miR-128-3p水平。用hsa-miR-128-3p模拟物转染HCM消除了TXL的保护作用。结论:miR-128-3p / p70s6k1信号通路参与了TXL对H / R期间HCM凋亡的保护作用。因此,p70s6k1的过表达是减轻心肌再灌注损伤的潜在新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号